شواهد الکتروفیزیولوژیکی در مورد کاهش تعادل دارویی در بیماری پارکینسون
ترجمه نشده

شواهد الکتروفیزیولوژیکی در مورد کاهش تعادل دارویی در بیماری پارکینسون

عنوان فارسی مقاله: ارتباط کلامی در مورد دوز دارویی که باعث کاهش تعادل دارویی در بیماری پارکینسون میشود: شواهد رفتاری و الکتروفیزیولوژیکی
عنوان انگلیسی مقاله: Verbal communication about drug dosage balances drug reduction in Parkinson’s disease: Behavioral and electrophysiological evidences
مجله/کنفرانس: بیماری پارکینسون و اختلالات مرتبط - Parkinsonism & Related Disorders
رشته های تحصیلی مرتبط: پزشکی
گرایش های تحصیلی مرتبط: مغز و اعصاب
کلمات کلیدی فارسی: بیماری پارکینسون، لوودوپا، عملکرد Motor، خستگی، پتانسیل آمادگی، اثر دارونما، اثر Nocebo
کلمات کلیدی انگلیسی: Parkinson’s disease، L-dopa، Motor performance، Fatigue، Readiness potential، Placebo effect، Nocebo effect
نوع نگارش مقاله: مقاله پژوهشی (Research Article)
نمایه: Scopus - Master Journals List - MedLine - JCR
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.parkreldis.2019.06.015
دانشگاه: Dept of Neuroscience, University of Turin Medical School, Turin, Italy
صفحات مقاله انگلیسی: 6
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2019
ایمپکت فاکتور: 4/348 در سال 2018
شاخص H_index: 84 در سال 2019
شاخص SJR: 1/639 در سال 2018
شناسه ISSN: 1353-8020
شاخص Quartile (چارک): Q1 در سال 2018
فرمت مقاله انگلیسی: PDF
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: دارد
کد محصول: E12818
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست مطالب (انگلیسی)

Abstract

1- Introduction

2- Materials and methods

3- Results

4- Discussion

References

بخشی از مقاله (انگلیسی)

Abstract 

Introduction: Changing drug dosage is common in clinical practice. Recent evidence showed that psychological factors may affect the therapeutic outcome. The aim of this study is to test whether verbal communication about drug dosage changes motor performance and fatigue in Parkinson's Disease (PD) patients. Methods: We performed clinical (Unified PD Rating Scale), motor (number of finger flexions and perceived fatigue), and electrophysiological measurements (readiness potential, RP) in PD patients during medication-off and medication-on conditions in three groups. The first group got a full dose of L-dopa and was told it was a full dose. The second group got half dose and was told it was half dose. The third group got half dose, but it was told it was a full standard dose. Results: We found that overt half dose was less effective than the full dose for clinical improvement, motor performance, and readiness potential. However, if half dose was given along with verbal instructions that it was a full dose, clinical improvement, motor performance and readiness potential were not significantly different from the full dose. Conclusions: Our findings indicate that verbal communication about dose reduction is as effective as the 50% dose reduction itself, demonstrating that deceptive information about the dose may have an important impact on the therapeutic outcome. Moreover, the supplementary motor area, source of the RP, seems to be involved in this psychological effect.

Introduction

Chronic use of L-dopa for treatment of Parkinson's Disease (PD) may lead to motor complications which can worsen the quality of life of PD patients and undermine the L-dopa therapy itself [1]. As changing drug dosage is common in clinical practice [2,3], one strategy may imply a Ldopa dose reduction, albeit it could be sometimes limited by patients' propensity for dopaminergic overtreatment [4]. Recent research uncovered the important role of psychological factors in drug response for PD patients and clarified some of the biological underpinnings. Both placebo and nocebo effects, respectively mediated by patient's positive and negative expectations, have been found to play a central role in the therapeutic outcome of these patients [5,6]. Furthermore, bradykinesia, rigidity, and resting tremor have shown to be particularly susceptible to placebo effect compared to other domains of PD impairment [7–9]. Supporting the crucial role of psychological factors in PD treatment are also the open-hidden studies, where the hidden administration of a drug has been found to be less or not at all effective compared to its administration in full view of the patient [10]. Interestingly, it has been recently showed that verbal communication about the cost of a treatment can affect PD patients’ expectations [11]. This study aims to understand the contribution of verbal instructions on the L-dopa response, specifically on motor performance and fatigue perception, in a cohort of PD patients. The L-dopa dose was thus halved, while manipulating patients’ expectations about drug dosage.